New: NCI-funded clinical trial search
Mednet Logo

For patients with clinically node-positive prostate cancer, would you consider adding a brachytherapy boost to external beam radiation and ADT?

Node-positive patients were not eligible for ASCENDE-RT, and the current NCCN guidelines do not list brachy boost as an option for regional risk group patients.
6 Answers
Mednet MemberInvited Expert
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center
Answered on

Absolutely not. Unless on a clinical trial.

Not only are these patients excluded from every brachy trial, there is essentially zero retrospective data. Thus you have essentially no data that this will help the patient. However, what you know is that it will increase cost and increase toxicity.

ASCENDE-RT and most dose-escalation trials have taught us an important lesson- the biggest bang for your buck for dose escalation is in intermediate (or even low risk disease) when competing risk of having micromets is lowest. It is a misconception that in high or very high risk that these patients benefit most. Patients with clinical N1 disease have very poor outcomes, and their natural history is not driven by local failure but by further nodal and di...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Radiation Oncology · Cedars-Sinai Medical Center
Answered on

We've had discussions about such patients (prostate in place and with cN+ disease) at our center. Can we extrapolate from ASCENDE-RT to patients with node positive disease and suggest a benefit to adding brachytherapy? In the absence of great trials, I tend to agree with @Dr. First Last that we can't simply extrapolate -- after all does it really make sense to intensify treatment to the prostate when there's gross nodal disease that will only be gently intensified with SIB? I'm not sure that it does.

However, we should be aware that treating the prostate with EBRT in the face of M1 disease has recently been shown to improve survival. That finding is a paradigm shift in prostate cancer and suggests that we should rethink our basic understand...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Radiation Oncology · Emory University School of Medicine
Answered on

Though not eligible for ASCENDE-RT and brachy boost not listed currently as option for clinically node+ prostate cancer, I do consider brachy boost in this situation.

As the volume of data demonstrating impact of loco-regional treatment in both the node+ and even metastatic setting grows, it does make sense to provide highest biological dose possible to prostate and that typically means brachy boost for high-risk prostate cancer.

This must of course be tailored to where the nodes are positive, as I tend to SIB them to a higher dose. Thus, if the nodes are close to the prostate/rectum I might be reluctant to do a brachy boost, but if the nodes are away from the brachy target (ie, if SIB dose + brachy dose is not prohibitively high) then brach...

Join for free or sign in to see the full answer

Mednet Member
Radiation Oncology · Coastal Radiation Oncology
Answered on

Bear in mind, it becomes difficult to criticize our urologic colleagues’ recommendations for prostatectomy in locally advanced, node positive or (even) M1 disease when we, ourselves, begin advocating for more aggressive (and potentially more toxic) local therapy in the absent of data.

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on

I have been reluctant to do brachy boost as absolute benefit additional local control in these pts would be small because of high and competing risk of distant Mets and need to consider increased morbidity with the procedure into equation also. If we extend brachy boost to node positive then with stampede trial showing improved survival with local RT for oligimets, one may extend same argument for brachy boost in these pts also.

Join for free or sign in to see the full answer

Mednet Member
Radiation Oncology · Community Care Physicians
Answered on · Updated on

There may be some merit to the argument of brachy in N1 pts. If we are going to treat the primary site for M1 pts, obviously there is benefit to control primary site. Brachy is most effective in local control, especially in high grade disease.

I will admit that I have not done brachy in N1 pts, but an argument may be made.

Join for free or sign in to see the full answer